Donanemab is a humanized monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) – pyroglutamate Aβ – which is found only in the brain amyloid plaques associated with Alzheimer’s Disease (AD). Donanemab works by inducing microglial-mediated clearance of existing Aβ plaques in order to slow the progressive decline in cognitive function associated with AD.
Donanemab Biosimilar Antibody
$205.00 – $2,500.00
Donanemab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human amyloid beta (Aβ) protein.
Host/Isotype: Human/IgG1
Class: Monoclonal
Immunogen: Human Aβ protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.